Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach

Bonfill, Xavier; Arevalo-Rodriguez, Ingrid; Garcia, Laura Martínez; Quintana, Maria Jesús; Buitrago-García, Diana; Urbina, Diego Lobos; Cordero, José Antonio
August 2018
Cancer Management & Research;Aug2018, Vol. 10, p2357
Academic Journal
Purpose: The purpose of this study was to provide evidence-based recommendations of intermittent androgen deprivation therapy (IADT) compared with continuous androgen deprivation therapy (CADT) for men with prostate cancer (PCA). Methods: We conducted a comprehensive search in MEDLINE, EMBASE, The Cochrane Library, CINAHL, and ECONLIT, from the database inception to December 2017. We adhered to the Grading of Recommendations, Assessment, Development and Evaluation framework to assess the quality of the evidence and to formulate recommendations. Results: We included one systematic review with 15 trials as well as three additional studies that assessed IADT versus CADT, all of them focused on PCA patients in advanced stages. The findings did not show differences for critical and important outcomes, including adverse events. Trials reported the benefits of IADT in terms of selected domains of health-related quality of life, although with high heterogeneity. Evidence quality was considered moderate or low for most of the assessed outcomes. We identified a patient preference study reporting a high preference for IADT, due to issues related to quality of life, general well-being, and side effects, among others. We did not identify economic studies comparing these regimes. We formulate four recommendations: one no-recommendation, one conditional recommendation, and two good practice points. Conclusion: For men in early stages of PCA, it is not possible to make any recommendation about the preferable use of IADT or CADT due to the lack of available evidence. For men in advanced stages of the disease, an IADT should be considered as soon as clinically reasonable (weak recommendation and low certainty of the evidence). Clinicians should discuss the risks and benefits of IADT and CADT with their patients, taking into account their values and preferences.


Related Articles

  • GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer. Naiki, Taku; Naiki-Ito, Aya; Asamoto, Makoto; Kawai, Noriyasu; Tozawa, Keiichi; Etani, Toshiki; Sato, Shinya; Suzuki, Shugo; Shirai, Tomoyuki; Kohri, Kenjiro; Takahashi, Satoru // Carcinogenesis;Sep2014, Vol. 35 Issue 9, p1962 

    GPX2 overexpression in CRPC increased cell growth through ROS regulation in a cell cycle-dependent manner. Moreover, patients with highly expressed GPX2 had significantly poorer prognosis. These findings suggest that GPX2 may be a prognostic marker and therapeutic target for CRPC.There is a need...

  • Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer -- going beyond PSA and imaging, a systematic literature review. Schmid, S.; Omlin, A.; Blum, D.; Strasser, F.; Gillessen, S.; Rothermundt, C. // Annals of Oncology;Nov2015, Vol. 26 Issue 11, p2221 

    Background: In the past years, there has been significant progress in anticancer drug development for patients with metastatic castration-resistant prostate cancer (CRPC). However, the current instruments to assess clinical treatment response have limitations and may not sufficiently reflect...

  • Is There a Role for Active Surveillance in Low-Risk Prostate Cancer? Augustin, Herbert; Mayerhofer, Katrin; Seles, Maximilian; Pummer, Karl // Urologia Internationalis;Sep2015, Vol. 95 Issue 2, p125 

    Background: Active surveillance (AS) represents an expectant treatment strategy for clinically localized prostate cancer (PCa) with low-risk features. Objective: The actual management as well as the pros and cons of AS were evaluated. Methods: A systematic review of the recent literature was...

  • Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. Houédé, Nadine; Beuzeboc, Philippe; Gourgou, Sophie; Tosi, Diego; Moise, Laura; Gravis, Gwenaëlle; Delva, Remy; Fléchon, Aude; Latorzeff, Igor; Ferrero, Jean-Marc; Oudard, Stéphane; Tartas, Sophie; Laguerre, Brigitte; Topart, Delphine; Roubaud, Guilhem; Agherbi, Hanane; Rebillard, Xavier; Azria, David // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: COU-AA-301 trial has proved that abiraterone acetate (AA), a selective inhibitor of androgen biosynthesis, improved overall survival (OS) of patients with metastatic castration resistant prostate cancer (mCRPC) after a first line of docetaxel. Based on this result, a Temporary...

  • Trial Probes Web-Based Behavior Change Tool for PCa Patients.  // Renal & Urology News;Oct2016, Vol. 15 Issue 8, p23 

    The article offers an overview of a randomized pilot study to examine how well a computer-based behavior change guide works in increasing physical activity in men with prostate cancer who have received androgen-deprivation therapy.

  • Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Ahmadi, Hamed; Daneshmand, Siamak // Patient Related Outcome Measures;2014, Vol. 5, p63 

    Androgen deprivation therapy (ADT) constitutes the irst-line treatment for patients with locally advanced tumors, recurrent or metastatic disease. Given its widespread use, clinicians should be familiar with common side effects of this treatment. This review focuses on common side effects of ADT...

  • Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Cerne, J Z; McGuire, S E; Grant, S R; Munsell, M F; Lee, A K; Kudchadker, R J; Choi, S L; Mahmood, U; Hoffman, K E; Pugh, T J; Frank, S J; Kuban, D A // Prostate Cancer & Prostatic Diseases;Dec2013, Vol. 16 Issue 4, p346 

    Background:In prostate cancer patients treated with androgen deprivation therapy (ADT) and radiation therapy (RT), a pre-RT PSA level 0.5 ng ml−1, determined after neoadjuvant ADT and before RT, predicts for worse survival measures. The present study sought to identify patient,...

  • Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Wozney, Jocelyn; Antonarakis, Emmanuel // Cancer & Metastasis Reviews;Sep2014, Vol. 33 Issue 2/3, p581 

    Treatments that target the androgen axis represent an effective strategy for patients with advanced prostate cancer, but the disease remains incurable and new therapeutic approaches are necessary. Significant advances have recently occurred in our understanding of the growth factor and signaling...

  • SEX LIFE IN PATIENTS WITH METASTATIC PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY. Ermeç, Bahadır; Taşkapu, Hakan Hakkı; Dinçer, Murat; Ortaç, Mazhar; Salabaş, Emre; Kadıoğlu, Ateş // Nobel Medicus Journal;may-aug2015, Vol. 11 Issue 2, p5 

    Prostate cancer is the most common cancer affecting men. Androgen deprivation therapy (ADT) is accepted as the primary treatment modality of advanced or metastatic prostate cancer Erectile dysfunction and loss of libido are well-known side effects of ADT. In the previous studies, androgens have...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics